Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2000

View Archived Issues

Amgen reviews third quarter developments

MGI Pharma to purchase Hexalen from MedImmune

Lorus seeks FDA approval to move GTI-2501 to clinical testing

Demerger of Novo Nordisk approved by shareholders

Pharmacia terminates collaboration with Epimmune for cancer vaccine development

Hemophilia gene therapy collaboration established by Targeted Genetics and Genetics Institute

Team from Roche Bioscience identifies new target for the treatment of overactive bladder

Tumor-selective DPD inhibitor Ro-09-4889 designed to enhance capecitabine efficacy

ERA-923: a new SERM developed for the treatment of metastatic breast cancer

Menarini investigates how sugar modifications affect antitumor activity of new anthracyclines

Genzyme Transgenics reacquires rights to rhATIII

New water-soluble quinazoline antitumor agent CB-300919 profiled at NCI-EORTC-AACR meeting

LU-135252 produces hemodynamic and neurohumoral benefits in advanced heart failure

Ribozyme offers pipeline overview, announces new hepatitis B product

AHA news: preclinical studies support use of PD-180988 for the management of pulmonary hypertension

Early clinical data support further development of sitaxsentan for PAH

Therapeutic and diagnostic use of new CD164-binding monoclonal antibody

Potent and safer antioxidants, and their use, claimed by Jenapharm

Research at Pacific leads to identification of potent new antiinflammatory agents

Canadian company presents new HIV integrase inhibitors

SCRAS issued patent for new series of somatostatin receptor modulators

Shionogi's U.S. subsidiary identifies specific antitumor agents with a cyanoguanidine structure

Akzo presents new LH receptor agonists and their use in controlling fertility

Recent patent discloses novel compounds particularly useful for asthma and rhinitis

Steroid-free eczema treatment recommended for FDA approval

Cellular effects and mechanism of action of new pteridine derivative discussed at NCI-EORTC-AACR

Company Profile: Peptor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...